ProteomeLab™ PF 2D Analysis of Genetically-Characterized Human Glioma Xenografts
Victoria Ioffe1, Ashken Movsisyan1, Jiuhong Yu1, C. David James2, and Oliver Bögler1
- William and Karen Davidson Laboratory, Hermelin Brain Center, Department of Neurosurgery, Henry Ford Hospital, Detroit, MI
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN
Materials and Methods
Two glioblastoma xenografts were established in the flanks of nude mice (C.D.J., manuscript in preparation). Tumor #6 over expresses ∆EGFR while Tumor #12 over expresses wild-type EGFR. Tumors were harvested and approximately 10 mg of wet tissue mass was lysed according to the protocol provided with the ProteomeLab PF 2D chemistry kit. Proteomic maps were generated with the ProteomeLab PF 2D system as previously described.
In summary, proteomic analysis of tumor samples with the ProteomeLab PF 2D system allows rapid and high-sensitivity resolution of proteins, thereby facilitating the identification of molecular differences and accelerating their exploitation by downstream technologies.
* All trademarks are the property of their respective owners. Where applicable, the PCR process is covered by patents owned by Roche Molecular Systems, Inc., and F. Hoffman-LaRoche, Ltd.
©1998
- 2006 Beckman Coulter, Inc.
